Cure8 research brief
A colon-targeted microcapsule could improve how drugs reach inflamed tissue in ulcerative colitis, potentially reducing stomach degradation and systemic side effects while increasing local effect.
Researchers, formulation scientists, and clinicians interested in colon-targeted drug delivery and ulcerative colitis therapies.
This article reports an experimental drug-delivery system tested in vitro and in mice (preclinical). The microcapsules showed low drug leakage at acidic pH and faster, controlled release at pH 7.4, plus higher encapsulation efficiency and yield for an optimized formulation.
The authors report that treated mice had lower NF-κB p65 levels and improved histology versus free drug, suggesting more targeted delivery and reduced systemic exposure in this model. These findings represent preclinical, proof-of-concept work showing a potential colon-targeted delivery approach; they do not establish safety or effectiveness in people.
Preclinical mouse data reported in a journal abstract — promising for formulation work but not evidence of human benefit. The article focuses on a formulation using olsalazine sodium in hydrogel microcapsules.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China - 22104046; Discipline Construction Fund of Northwest Minzu University - 31920250002; Open Fund Project of Northwest Minzu University - 31920260052; Gansu Province Major Special Projects Program - 26ZDFA003
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK,...
This study shows the appendix is often inflamed early in conventional UC and then remodels to fibrous obliteration over decades, implying the appendix may matter more in early disease. Differences between conventional UC...
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
